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APOBEC3 deaminases (A3s) provide mammals with an anti-retroviral barrier by catalyzing dC-
to-dU deamination on viral ssDNA. Within primates, A3s have evolved diversely via gene 
duplications and fusions. Human APOBEC3C (hA3C) efficiently restricts the replication of viral 
infectivity factor (vif)-deficient Simian immunodeficiency virus (SIVΔvif), but for unknown 
reasons, it inhibits HIV-1Δvif weakly. In catarrhines (Old World monkeys and apes), the A3C 
loop 1 displays the conserved amino acid pair WE, while the corresponding consensus 
sequence in A3F and A3D is the largely divergent pair RK, which is also the inferred ancestral 
sequence for the last common ancestor of A3C|D|F in primates. Here, we report that 
modifying the WE residues in hA3C loop 1 to RK leads to stronger interactions with ssDNA 
substrate, facilitating catalytic function, which resulted in a drastic increase in both 
deamination activity and the ability to restrict HIV-1 and LINE-1 replication. Conversely, the 
modification hA3F_WE resulted only in a marginal decrease in HIV-1Δvif inhibition. The two 
series of ancestral gene duplications that generated A3C, A3D-CTD and A3F-CTD allowed 
neo/subfunctionalization: A3F-CTD maintained the ancestral RK residues in loop 1, while 
strong evolutionary pressure selected for the RKWE modification in catarrhines A3C, 
possibly allowing for novel substrate specificity and function. 
 
Keywords: APOBEC3C, APOBEC3F, Sooty Mangabey monkey, cytidine deaminase, 
deamination-dependent virus restriction, human immunodeficiency virus (HIV), LINE-1, gene 
duplication, paralogs, evolution
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AUTHOR SUMMARY  
The restriction factors of the APOBEC3 (A3) family of cytidine deaminases inhibit 
the replication of Vif-deficient retroviruses mainly by mutating their viral genomes. While 
there are seven A3 proteins (A3A-A3H) found in humans only A3G and A3F potently 
inhibit HIV-1 replication. A3C in general and its retroviral restriction capacity have not been 
widely studied probably due to its weak anti-HIV-1 activity, however, it displays a strong 
antiviral effect against SIV. Understanding the role of A3C is important because it is highly 
expressed in CD4+ T cells, is upregulated upon HIV-1 infection, and is distributed cell-wide. In 
this study, we report that replacing two residues in loop 1 of A3C protein with conserved 
positively-charged amino acids enhance the substrate DNA binding, which markedly facilitates 
its deamination-dependent antiviral activity against HIV-1 as well as increasing the restriction 
of LINE-1 retroelements. Furthermore, our evolutionary analysis demonstrates that the 
pressure that caused the loss of potential loop 1 residues occurred only in A3C but not 
in primate homologues. Overall, our study highlights the possibility of A3C acting as 
a super restriction factor, however, this was likely evolutionarily selected against to achieve a 
balance between anti-viral/anti-LINE-1 activity and genotoxicity.  
 
INTRODUCTION 
The APOBEC3 (A3) family of single-stranded (ss) DNA cytidine deaminases builds an intrinsic 
immune defense against retroviruses, retrotransposons, and other viral pathogens [1-4]. 
There are seven human A3 proteins (A3s) that possess either one (A3A, A3C, and A3H) or two 
(A3B, A3D, A3F, and A3G) zinc (Z)-coordinating DNA cytosine deaminase motifs, HXE[X23-
28]PC[X2-4]C (where X indicates a non-conserved position) [5-7]. A3G was identified as a factor 
capable of restricting infection of HIV-1 lacking Vif (viral infectivity factor) protein in non-
permissive T cell lines whose biochemical properties and biological functions were extensively 
studied [3,8-11].  
The encapsidation of A3 into the viral particles is crucial for virus inhibition [12-17]. During 
reverse transcription, viral core-associated A3 enzymes can deaminate cytidines (dC) on the 
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retroviral ssDNA into uridines (dU). These base modifications in the minus DNA strand cause 
coding changes and premature stop codons in the plus-strand viral genome (dGdA 
hypermutation), which impair or suppress viral infectivity [2,9,18-21]. In addition to the 
mutagenic activity of the viral-incorporated A3 enzyme, deaminase-independent mechanisms 
of restriction were also manifested by impeding reverse transcription or inhibiting DNA 
integration [22-27]. To counteract A3 mediated inhibition, lentiviruses evolved the Vif protein, 
which physically interacts with A3s to target them for polyubiquitination and proteasomal 
degradation, and thereby depleting the cellular A3s [28-30]. These A3-Vif interactions are 
often species-specific [31-35]. 
A3D, A3F, A3G, and A3H were shown to restrict HIV-1 lacking vif (HIV-1Δvif) [2,35-39]. 
Recently, mutation signatures resulting from the catalytic activity of nuclear localized A3s 
(especially A3A, A3B, and likely A3H) were reported in several cancer types [40,41] (for 
reviews, see: [42-45]. However, the A3C, which is distributed in both cytoplasm and nucleus 
[46] seems not to be a causative agent of chromosomal DNA mutations. Human A3C is known 
to act as a potent inhibitor of Simian immunodeficiency virus from African green monkey 
(SIVagm) and SIVmac (from rhesus macaque), limits the infectivity of herpes simplex virus, 
certain human papillomaviruses, murine leukemia virus, Bet-deficient foamy virus, and 
hepatitis B virus and represses the replication of LINE-1 (L1) retrotransposons [46-56]. 
However, the restrictive role of A3C on HIV-1 is marginal and there are several contradictory 
findings regarding its viral packaging and cytidine deamination activity [39,47,57-59]. Notably, 
A3C is expressed ubiquitously in lymphoid cells [5,47,60,61]. mRNA expression levels of A3C 
were found to be higher in HIV-infected CD4+ T lymphocytes [39,47], and significantly elevated 
in elite controllers with respect to ART-suppressed individuals [62]. A3C was found to 
moderately deaminate HIV-1 DNA if expressed in target cells of the virus and rather increased 
viral diversity than caused restriction [60].  
The crystal structure of A3C and its HIV-1 Vif-binding interface were reported recently [63]. 
The study revealed several key residues in the hydrophobic V-shaped groove formed by the 
2 and 3 helices of A3C that facilitate Vif binding resulting in proteasome-mediated 
degradation of A3C [63]. We extended this finding and identified additional Vif interaction 
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sites in 4 helix of A3C [64]. Other than a previous study that predicted putative DNA substrate 
binding pockets [52], biochemical and structural aspects of A3C enzymatic activity and their 
relevance for antiviral activity are not well investigated to date [3,4].  
Recently, we have shown that increasing the catalytic activity of A3C by an S61P substitution 
(based on the structural homology found between A3C and A3F at their C-terminal domain, 
A3F-CTD) is not sufficient to inhibit HIV-1Δvif [65]. It is unclear why A3C can potently restrict 
SIVΔvif, but not HIV-1Δvif despite the fact that the wild-type human enzyme possesses 
reasonable catalytic activity and encapsidates efficiently into retroviral particles [65]. Here we 
set out to understand the function of A3C in the context of HIV-1 inhibition. We generated a 
synthetic open reading frame derived from sooty mangabey monkey genome (smm, 
Cercocebus atys (torquatus) lunulatus), encoding for an A3C-like protein (hereafter called 
smmA3C-like protein) capable of restricting HIV-1 to similar or higher extent than human A3G. 
This A3C-like protein was reported to be resistant to HIV-1 Vif-mediated depletion [64]. Using 
this smmA3C-like protein as a tool, here we dissect the structure-function of hA3C and identify 
the crucial regions of A3C that facilitate stronger inhibition of HIV-1.  
 
RESULTS 
Identification of an A3Z2 protein with enhanced antiviral activity 
To determine whether A3C from non-human primates can potently restrict HIV-1Δvif 
propagation, we produced HIV-1Δvif luciferase reporter virus particles with A3C (an A3Z2 
protein) from human, rhesus macaque, chimpanzee (cpz), African green monkey (agm), with 
human A3G (an A3Z2-Z1, double domain protein), or a synthetic smmA3C-like protein and 
tested their viral infectivity. Viral particles were pseudotyped with the glycoprotein of 
Vesicular stomatitis virus (VSV-G) and normalized by reverse transcriptase (RT) activity before 
infection. The luciferase enzyme activity of infected cells was quantified two days post 
infection. Figure 1A shows the level of relative infectivity of HIV-1Δvif in the presence of the 
tested A3C proteins and hA3G. Human, rhesus, chimpanzee, and African green monkey A3C 
proteins reduced the relative infectivity of HIV-1Δvif similarly by approximately 60 to 70%. 
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Conversely, smmA3C-like protein inhibited HIV-1Δvif replication by more than one order of 
magnitude (Fig. 1A). Human A3G served as a positive control. Expression of the A3s in viral 
vector-producing cells showed that expression levels of smmA3C-like protein and agmA3C 
were lower than those of A3Cs from human, rhesus, and cpz (Fig. 1B). Viral incorporation of 
smmA3C-like protein was found to be very similar to hA3G, but much less efficient compared 
to hA3C (Suppl. Fig. S1A). 
The smmA3C-like construct was originally described to express A3C of smm [64]. However, 
using alignments of primate A3Z2 and related A3 proteins, we later found that the generated 
open reading frame consists of exons encoded by genes of smmA3C and smmA3F. In the 
smmA3C-like construct, the first “exon” (encoding for amino acids 1MNPQIR6) and last “exon” 
(encoding for amino acids 153FKYC to EILE190) were derived from smmA3C (smmA3C exon 1 
and exon 4) while the second “exon” (encoding for amino acids 7NPMK to FRNQ58) and third 
“exon” (encoding for amino acids 59VDPE to VDPE151) in smmA3C-like were of smmA3F origin 
(smmA3F C-terminal domain, CTD, exon 5 and exon 6) (Suppl. Fig. S2). Poor annotation of the 
smm genome and the high sequence similarity let us fuse these exons that were derived from 
smmA3C and smmA3F during the amplification step. To compare smmA3C-like to the wild-
type proteins, we cloned the genuine smmA3C and smmA3F-CTD and tested their activity. We 
found that only the smmA3C-like protein and not smmA3C protein showed enhanced cytidine 
deaminase activity (Suppl. Fig. S3). The smmA3F-CTD construct failed to express detectable 
levels of protein in transfected cells (Suppl. Fig. S3). 
To study G-to-A mutations on the plus-strand of viral DNA triggered by A3 in vivo activity, we 
routinely used a method called “3D-PCR” [65,66]. DNA sequences in which the cytosines were 
deaminated by A3 activity contain less GC base pairs than non-edited DNA, resulting in a lower 
melting temperature than the original, non-edited DNA. Therefore, successful amplification at 
lower denaturation temperatures (Td) (83.5 - 87.6°C) by 3D-PCR is indicating the presence of 
A3-edited sequences. Because restriction of HIV-1Δvif by smmA3C-like protein was similar or 
slightly stronger than restriction by hA3G (Fig. 1A), we analyzed the DNA editing capacity of 
these A3s during infection by 3D-PCR on the viral genome. 3D-PCR amplification with samples 
of cells infected with HIV-1Δvif viruses encapsidating hA3C, rhA3C, cpzA3C, or agmA3C yielded 
amplicons until Td 86.3°C, whereas the activity of smmA3C-like protein on the same substrate 
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allowed to produce amplicons at lower Td, 84.2°C. In control reactions using virions produced 
in the presence of hA3G, PCR amplification of viral DNA was detectable at lower Td (85.2°C 
and weakly at 84.2°C) (Fig. 1C). Importantly, using the vector control sample (no A3), PCR 
amplicons could be amplified only at higher Td (87.6°C). In our previous study, we elaborately 
compared the hypermutation load and patterns induced by A3C, A3G, and A3F in retroviruses 
and found that in HIV-1Δvif, the GA mutation rate induced by hA3C and A3C.S61P (Suppl. 
Fig. S4, an A3C mutant with enhanced deamination activity against SIVagmΔvif) was about 6%, 
whereas A3G and A3F triggered mutation rate was above 15% [65]. To study the effect of 
smmA3C-like protein in HIV-1Δvif, PCR products generated on smmA3C-like protein-edited 
samples formed at 84.2°C were cloned and independent clones were sequenced. smmA3C-
like protein caused hypermutation in HIV-1Δvif with a rate of 17.16% and predominantly 
favored the expected GA dinucleotide context (Suppl. Fig. S5). In addition, we have applied 
qualitative in vitro cytidine deamination assays using A3 proteins isolated from HIV-1Δvif and 
SIVagmΔvif viral particles [67,68]. This PCR-based assay depends on the sequence change 
caused by A3 converting a dCdU in an 80-nucleotide (nt) ssDNA substrate harboring the 
A3C-specific TTCA motif. Catalytic deamination of dCdU by A3C is then followed by a PCR 
that replaces dU by dT generating an MseI restriction site. The efficiency of MseI digestion 
was monitored by using a similar 80-nt substrate containing dU instead of dC in the 
recognition site. As expected, hA3C and hA3C.S61P, encapsidated into the HIV-1Δvif particles, 
did not yield a considerable product resulting from ssDNA cytidine deamination [65], however, 
smmA3C-like protein formed high amounts of deamination products (Fig. 1D). Using smmA3C-
like protein, the deamination products were observed even after transfection of 10-fold 
smaller amounts of expression plasmid during virus production. In contrast, A3C and A3C.S61P 
proteins isolated from SIVagmΔvif particles but not from HIV-1Δvif particles produced the 
expected deamination products, whereas smmA3C-like protein exhibited the strongest 
catalytic activity, regardless of the source (Fig. 1D). Taken together, we conclude that 
smmA3C-like protein inhibits HIV-1 by cytidine deamination causing hypermutation of the 
viral DNA.  
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Identification of the regulatory domain of smmA3C-like protein that mediates HIV-1 
restriction 
Amino acid sequence identity and similarity between hA3C and smmA3C-like protein reach 
77.9% and 90%, respectively (Suppl. Fig. S4A). To facilitate the identification of distinct 
determinants of smmA3C-like protein that confer HIV-1 inhibition, ten different 
hA3C/smmA3C-like chimeras were constructed [64] (Fig. 2A). We first tested the anti-HIV-
1Δvif activity of these A3C chimeras. Viral particles containing different chimeric proteins were 
produced and their infectivity was tested. As shown in Fig. 2B, chimeras C2, C4, and C8 strongly 
reduced the infectivity of HIV-1Δvif. Especially, chimera C2 (hA3C harboring a swap of 36 
residues of the smmA3C-like protein at the N-terminal end) inhibited HIV-1Δvif replication by 
about two orders of magnitude. On the contrary, chimeras C6 and C9 reduced viral infectivity 
by 72% relative to vector control (Fig. 2B). 
Next, we determined the intracellular expression and virion incorporation efficiency of the 
chimeras by immunoblotting. Chimeras C2, C3, C5, C7, and C9, which contain residues 37 to 
76 of hA3C (Fig. 2A), were more highly expressed than C1, C4, C6, and C10 (Fig. 2C). 
Specifically, chimera C2 displayed higher protein levels than hA3C while C10 was below the 
detection threshold. Chimeras, C2, C4, C6, C7, and C9 were found to be encapsidated in HIV-
1Δvif (Fig. 2C, viral lysate). In particular, C3 and C5 were less efficiently packaged into viral 
particles although they were present at higher intracellular expression levels. Conversely, C6 
produced less protein but its viral incorporation was higher than that of C3 or C5. In addition, 
we analyzed the in vitro cytidine deaminase activity of these chimeras as described above (Fig. 
2D). Here we used lysates of transfected HEK293T cells to readily evaluate the catalytic activity 
of the chimeric A3Cs. As demonstrated in Fig. 2D, only the amounts of deamination products 
predominantly generated by C2 and C4 were similar to those produced by smmA3C-like 
protein.  
Taken together, chimeras C2 and C4 strongly restricted HIV-1Δvif and are characterized by 
corresponding in vitro deamination activity. C6, by contrast, lost any antiviral and deamination 
activity, suggesting that the N-terminal region of smmA3C-like protein is crucially involved in 
the antiviral mechanism. We speculate that residues in C2 and C4 that are absent in C6 
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complemented the restriction activity of these chimeras. Due to its superior antiviral activity 
we mainly focused on chimera C2 in our following experiments. 
 
Synergistic effects of residues in the RKYG motif of chimera C2 and smmA3C-like protein 
govern their potent antiviral activity  
To identify the specific residues in C2 that are essential for its anti-HIV-1 activity, we targeted 
two N-terminal motifs of C2, namely 13DPHIFYFH20 (shortly “DHIH”) and 24LRKAYG29 (named 
“RKYG”) as presented in the sequence alignments of Suppl. Fig. S4A, and generated more 
variants of C2 by swapping one, two, or four amino acids with the analogous residues of hA3C 
as presented in Fig. 3A. First, we cloned the C2 variants C2.DH-YG (YGTQ motif of helix 1) and 
C2.RKYG-WEND (WEND motif of loop 1, see A3C alignment and ribbon diagram Suppl. Fig. S4) 
and tested their anti-HIV-1 and deamination activity. This pilot experiment revealed that loop 
1 motif RKYG but not 1 helix motif DHIH in C2 is essential for its activity (data not shown). 
Hence, we constructed the mutants C2.R25W, K26E, Y28N, and G29D (Fig. 3A) and tested 
them for catalytic and antiviral activity. Since the in vitro deaminase activity of the chimeras 
C1 to C10 correlated with their antiviral activity (Fig. 2B and 2D), we expressed these variants 
of C2 in HEK293T cells and performed in vitro deamination assays. The results of the 
deamination assay clearly demonstrated that the DH motif in C2 is not relevant for its potent 
catalytic activity as the C2.DH-YG acted similar to C2 (Fig. 3B), but mutation of the RKYG motif 
in the RKYG-WEND variant resulted in a loss of deamination activity (Fig. 3B). Interestingly, 
none of the single amino acid changes in RKYG (C2.R25W, K26E, Y28N, and G29D) resulted in 
the loss-of-function of C2, albeit the catalytic activities of R25W and K26E were partially 
reduced (Fig. 3B). Consistent with the data obtained from the in vitro assay, the chimeric 
C2.RKYG-WEND variant failed to restrict the infectivity of HIV-1Δvif, while C2 and its point 
mutants strongly inhibited the virus (Fig. 3C). Immunoblot analysis of cell and viral lysates 
further confirmed that cellular expression and viral encapsidation of these variants were 
comparable (Fig. 3D). Finally, to test the in vivo DNA editing capacity, we did 3D-PCR analysis 
using C2, C2.DH-YG, and C2.RKYG-WEND variants. As presented in Fig. 3E, only HIV-1Δvif 
particles produced in the presence of A3C chimera C2 and its mutant C2.DH-YG harbored viral 
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DNA that was detected by PCR products at low-denaturation temperature and C2.RKYG-
WEND behaved similarly to the vector control (Fig. 3E). Likewise, replacing RKYG with WEND 
in the smmA3C-like protein inhibited its antiviral activity (Figs. 4A and 4B) and deamination 
activity of HIV-1 genomes (Fig. 4C) as did the active site mutant E68A. 
 
The WE-RK mutation in loop 1 of hA3C determines its strong deaminase-dependent antiviral 
function 
Mutational changes of the RKYG motif to WEND residues in loop 1 of C2 and smmA3C-like 
protein resulted in complete loss of enzymatic functions and anti-HIV-1 activities (Figs. 3C and 
4A). To identify the residues in hA3C that are critically required for the deaminase-dependent 
antiviral activity against HIV-1Δvif, we modified the loop 1 of hA3C with 25WE26>>25RK26 and 
28ND29>>28YG29 residues and compared their antiviral capacity (please see A3C alignment and 
ribbon diagram Suppl. Fig. S4). As controls, we included additional mutants such as a 
catalytically inactive Zn2+-coordinating C97 mutant, A3C.C97S [52], and the variants A3C.S61P 
[65] and A3C.S188I [69] (Suppl. Fig. S4A) exhibiting enhanced deaminase activity. Compared 
to wild-type hA3C, WE-RK greatly enhanced inhibition of HIV-1Δvif, and the ND-YG variant 
behaved like wild-type A3C, while S61P and S188I have demonstrated only marginally 
increased HIV-1Δvif restriction (Fig. 5A). Importantly, mutant A3C.C97S did not inhibit HIV-
1Δvif (Fig. 5A).  
Next, we generated active site mutants to analyze if the antiviral activity of A3C.WE-RK is 
deamination-dependent. To achieve this, we introduced a C97S mutation in each of these 
constructs. Additionally, we compared the ancillary effect of mutants such as S61P [65] and 
S188I [69] by introducing these mutations in the WE-RK variant of A3C. As expected, the 
inhibitory activities of A3C.WE-RK, A3C.WE-RK.S61P, and A3C.WE-RK.S61P.S188I against HIV-
1Δvif were abolished by active site ablating mutation C97S, indicating the importance of the 
enzymatic activity of A3C (Fig. 5B). Introducing either the single mutation S61P or the double 
mutation S61P.S188I did not considerably change the action of A3C.WE-RK (Fig. 5B). 
Immunoblot analysis of cell and viral lysates demonstrated that hA3C and all mutants (except 
A3C.WE-RK.S61P.S188I.C97S mutant) expressed a comparable level of protein (Fig. 5C). 
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However, viral incorporation of A3C.C97S, A3C.WE-RK.C97S, A3C.WE-RK.S61P.C97S, and WE-
RK.S61P.S188I.C97S was slightly decreased relative to that of wild-type and mutant proteins 
that do not contain the C97S mutation (Fig. 5C). Moreover, we confirmed the effects of these 
mutants on HIV-1Δvif propagation by 3D-PCR (Fig. 5D) and deamination assay in vitro (Fig. 5E). 
In both assays, we found that the C97S mutation destroys the function of all A3C variants. 
Thus, we conclude that the loop 1-mediated enhanced activity of hA3C.WE-RK is dependent 
on catalytic deamination.  
 
The RK-WE mutation in loop 1 moderately reduces the antiviral activity of hA3F 
The residues 25RK26 in loop 1 of smmA3C-like protein are derived from exon 5 of A3F gene in 
which exon 5 to 7 encoding A3F-CTD and conserved in primate A3F proteins (Suppl. Fig. S2). 
Various loops within A3F-CTD were recently investigated with respect to their role in substrate 
binding and enzyme function [70] but it was not possible to unravel the antiviral activity of 
A3F-CTD, mainly due to difficulties in expressing this domain in human cells as found earlier 
[65,71]. hA3C and hA3F-CTD display 77% sequence similarity, reflecting a common 
evolutionary origin [6]. Importantly, the antiviral activity of hA3F is mediated by its CTD 
[72,73]. To test the impact of RK residues in loop 1 of the hA3F-CTD, we compared the antiviral 
activity of hA3F with A3F.RK-WE against HIV-1Δvif. hA3F and hA3F.RK-WE expressed similar 
amounts of protein and were equally encapsidated in HIV-1 particles (Fig. 6A). However, 
A3F.RK-WE exhibited an about two-fold decreased capacity to inhibit HIV-1Δvif compared with 
wild-type A3F (Fig. 6B). Consequently, A3F.RK-WE showed decreased mutation efficiency 
compared with wild-type A3F (Figs. 6C and 6D), which was consistent with data presented in 
a recent report [70]. Thus, we conclude that loop 1 with its residues RK in CTD of A3F is 
important for hA3F’s enzymatic function.  
 
Inhibition of LINE-1 retrotransposition by A3C variants  
Since A3C and A3F restrict endogenous LINE-1 (L1) retrotransposition activity by 40-75% and 
66-85% [46,56,74,75], respectively, we set out to elucidate how the WE and the RK residues 
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in loop 1 of both hA3C and hA3F, respectively, affect the L1 inhibiting activity. To this end, we 
quantified the L1-inhibiting effect of human wild-type A3A, A3C, and A3F proteins and their 
mutants hA3C.WE-RK, hA3C.WE-RK.S61P, and hA3F.RK-WE by applying a dual-luciferase 
retrotransposition reporter assay [76]. In this cell culture-based assay, the firefly luciferase 
gene is used as the reporter for L1 retrotransposition and the Renilla luciferase gene is 
encoded on the same plasmid for transfection normalization (Fig. 7A). Consistent with 
previous reports, overexpression of hA3A, hA3C, and hA3F resulted in inhibition of L1 reporter 
retrotransposition by approximately 94%, 68%, and 56%, respectively (Fig. 7B). The mutant 
hA3C.WE-RK displayed an increased L1-restricting effect (from 56% to ~96%), and the 
introduction of the additional mutation hA3C.WE-RK.S61P did not further increase the ability 
of the enzyme to restrict L1 mobilization (Fig. 7B). Notably, hA3F and the mutant hA3F.RK-WE 
exhibited a comparable level of L1 restriction, indicating that regions other than loop 1 of A3F-
CTD and, probably, the NTD (N-terminal domain) of hA3F are involved in L1 restriction (Fig. 
7B). Immunoblot analysis of cell lysates of co-transfected HeLa-HA cells demonstrated 
comparable expression of the L1 reporter and HA-tagged A3- and A3 mutant proteins (Suppl. 
Fig. S7). These findings indicate that the WE-RK mutation in hA3C enhances its L1 inhibiting 
activity. Based on the observed antiviral activity and the L1 restricting effect of hA3C.WE-RK 
on L1, we hypothesize that the introduction of these positively charged residues in hA3C 
significantly fosters its interaction with nucleic acids, which was recently reported to mediate 
its L1 inhibiting activity [56]. 
 
The positively charged residues R25 and K26 in A3C-C2 form salt-bridges with the backbone 
of the ssDNA  
The structural model of hA3C variant C2 binding to ssDNA, which is based on the ssDNA-bound 
crystal structure of A3A, shows a cytidine residue in the active center of hA3C-C2 (Fig. 8A). 
However, the ssDNA fragment, which was co-crystallized with hA3A, is too short to interact 
with residues 25, 26, 28, and 29, which differ between hA3C WT and the C2 variant. Hence, 
this binding mode model cannot explain why C2 has a higher cytidine deaminase activity than 
hA3C WT. To assess the binding to a longer ssDNA fragment, we generated a complex model 
of ssDNA bound to the NTD of rhesus macaque A3G (rhA3G) [77], similar to the ssDNA-bound 
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A3F-CTD model built previously [78], and aligned the crystal structure of hA3C WT and the 
model of C2 to this complex (Figs. 8B, 8C, and 8D). The positively charged residues R25 and 
K26 in C2 form salt-bridges with the backbone of the ssDNA (Fig. 8D) in contrast to hA3C WT 
(Fig. 8C). Additionally, Y28 of C2 can form π-π-stacking interactions with the aromatic DNA 
bases (Fig. 8D). Thus, these three residues can form stronger interactions with ssDNA in C2 
than their counterparts in hA3C. This finding may explain the enhanced cytidine deaminase 
activity of C2 compared to hA3C. 
Furthermore, we performed five replicas of molecular dynamics (MD) simulations of 2 µs 
length each for hA3C, C2, and hA3C.S61P.S188I to assess the structural impact of the 
substitutions. The root mean square fluctuations (RMSF), which describe atomic mobilities 
during the MD simulations, show distinct differences between the variants in the putative 
DNA-binding regions of the proteins: the RMSF of C2 and hA3C.S61P.S188I are up to 2 Å larger 
compared to hA3C WT in the regions carrying the substitutions (residues 21-32 for C2 and 
residues 55-67 for hA3C.S61P.S188I) (Suppl. Fig. S8). This effect is specifically related to the 
respective substitutions, as no change in RMSF occurs for a variant in a region where it is 
identical to A3C WT. The increased movement of ssDNA-binding residues might improve the 
sliding of C2 and hA3C.S61P.S188I along the ssDNA, owing to more transient interactions with 
the ssDNA backbone. Conversely, the RMSF of loop 7 is up to 1 Å lower in both the C2 and 
hA3C.S61P.S188I variants compared to the hA3C WT (Suppl. Fig. S8). 
 
WE-RK mutation in the loop 1 of hA3C enhances the interaction with ssDNA  
To validate our structural modeling analysis (Fig. 8), and to address if the interaction of hA3C 
and hA3C.WE-RK with the substrate ssDNA was differentially affected, we performed 
electrophoretic mobility shift assays (EMSA) using hA3C-GST (A3C fused to glutathione S-
transferase, GST) and hA3C.WE-RK-GST purified from HEK293T cells (Fig. 9A). As a probe, we 
used a biotin-labeled ssDNA oligonucleotide that harbors a TTCA motif in its central region 
[65,79]. Because hA3C-GST is known to form a stable DNA-protein complex when the protein 
concentration reaches ≥ 20 nM ([65] and data not shown), we decreased the amount of A3C 
and its mutant protein to specifically test their inherent DNA binding capacity. In a titration 
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 





experiment with concentrations ranging from 2 to 8 nM in steps of 2 nM of hA3C-GST and 
hA3C.WE-RK-GST purified protein, we detected a clear trend in the formation of DNA–protein 
complexes for hA3C-GST and hA3C.WE-RK-GST (Fig. 9B). Intriguingly, DNA-protein complexes 
of hA3C.WE-RK-GST started appearing at the lowest protein concentration used (2 nM), while 
hA3C-GST-DNA complexes were detected at protein concentration ≥ 6 nM. The top-shifted 
complexes were formed only with hA3C.WE-RK-GST and not with hA3C-GST. To confirm the 
specificity of the DNA–protein complexes, we competed for the reaction with unlabeled DNA 
carrying the same nucleotide sequence as the used probe in 500-fold excess relative to that 
probe. The addition of the competitor DNA to the sample containing the maximum (8 nM) 
amount of A3C protein, efficiently disrupted the protein-DNA complex formation. Together, 
data from structural modeling and EMSA experiments allowed us to conclude that the two 
amino acid-change in loop 1 of A3C boosts the ssDNA binding capacity of A3C. Importantly, 
the GST moiety did not affect the binding ([65] and data not shown). 
 
Evolution of A3Z2 loop 1 regions in primates  
We performed a phylogenetic reconstruction for the A3Z2 domains in primates, using the 
A3Z2 sequences in the northern tree shrew as outgroup. Because in primates A3D and the A3F 
contain two Z2 domains, we analyzed at the A3Z2 domain level (N- and C- terminal Z2) (Fig. 
10A). Our results show that the A3Z2 domains underwent independent duplication in the two 
sister taxa, tree shrews and primates: the three A3Z2 tree shrew sequences constitute a clear 
outgroup to all primate A3Z2 sequences. We identified a sharp clustering of the A3D-NTD and 
A3F-NTD on the one hand and of A3C, A3D-CTD, and A3F-CTD on the other hand. As to New 
World monkeys (Platyrrhini), we could only confidently retrieve A3C sequences from the 
white-faced sapajou Cebus capucinus and from the Ma's night monkey Aotus nancymaae. 
These sequences from A3C New World monkeys were basal to all Catarrhini (Old World 
monkeys and apes) A3C, A3D-CTD and A3F-CTD sequences, suggesting that the two gene 
duplications leading to the extant organization of A3C, A3D, and A3F occurred after the 
Platyrrhini/Catarrhini split 43.2 Mya (41.0 - 45.7 Mya) and before the 
Cercopithecoidea/Hominoidea split 29.44 Mya (27.95 - 31.35 Mya). The results show a tangled 
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distribution within the A3D-NTD and A3F-NTD clade, and within the A3D-CTD and A3F-CTD 
clade. These confusing relationships are more obvious when comparing an unconstrained Z2 
tree with a tree in which monophyly of the large six clades identified was enforced. 
Conversely, Catarrhini A3C sequences form a monophyletic taxon, and this A3C gene tree 
essentially adheres to the corresponding species tree (Fig. 10B). Focusing on the nodes that 
we could identify with confidence, we performed ancestral phylogenetic inference of the most 
likely amino acid sequence for the A3 loop 1 as well as consensus analysis of the extant 
sequences. Our results recover the well-conserved aromatic stacking stretch F[FY]FXF 
characteristic of all A3s. In the A3C, A3D-CTD, and A3F-CTD clade, we identified a motif with 
divergent evolution flanked by conserved small hydrophobic amino acids. The most likely 
ancestral form is the amino acid motif LRKA, which is also the form present in extant New 
World monkeys A3C and the most common in extant A3F-CTD; in the extant A3D-CTD the Arg 
residue is less conserved in L[RLQ][KT]A; and strikingly, in the ancestor of Catarrhini A3C, this 
motif changed to LWEA. Only subsequently, and exclusively in the Chlorocebus lineage, this 
change was partly reverted to LREA by a transition TGG>CGG. This reversion should have 
occurred after the divergence within Cercopithecinae, around 13.7 Mya (10.7 - 16.6 Mya). 
 
DISCUSSION 
Compared to the studies conducted over the past decade on the potent HIV-1 restriction 
factors A3G and A3F, investigations on A3C are very limited. Only a few recent studies have 
addressed the catalytic activity and substrate binding capacity of A3C [65,69,80]. While the 
previously characterized hA3C mutants S61P and S188I boost the catalytic activity of the 
enzyme to a certain level, none of these mutations are decisive because they do not reduce 
the HIV-1Δvif infectivity to any level accomplished by A3G nor do they directly partake in 
catalytic activity [65,69,80]. Because our repeated attempts to express A3F-CTD in human cells 
were not successful ([65] and Suppl. Fig. S3), we assayed A3C proteins from different Old 
World monkey species. Due to the high level of nucleotide sequence identity between the A3 
paralogs in the sooty mangabey monkey genome, we unintentionally generated the smmA3C-
like protein with superior anti-HIV-1 and enzymatic activity. We have identified the key role 
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of two positively-charged residues in loop 1 of the smmA3C-like protein (and of the hA3F-
CTD), namely R25 and K26 in the RKYG motif. Replacing RKYG of A3C chimera C2 or smmA3C-
like protein by the WEND (form of this motif in hA3C) abolished both their anti-HIV-1 and 
catalytic activity. Notably, the converse strategy of introducing the substitution WE-RK in the 
loop 1 of hA3C rendered hA3C.WE-RK a potent, deaminase-dependent, anti-HIV-1 enzyme. 
Consistent with these observations, our EMSA data clearly demonstrate that residues in the 
loop 1 of A3C regulate protein-DNA interaction and we postulate that this interaction is 
causative for the enhanced deamination activity and enhanced anti-HIV and L1 activity. A 
similar model was discussed by Solomon and coworkers, which demonstrated that loop 1 
residues of hA3G-CTD-2K3A-E259A (a catalytically inactive form of A3G-CTD) strongly interact 
with substrate ssDNA and that this distinguishes catalytic binding from non-catalytic binding 
[81]. Interestingly, loop 1 of A3A was found to be important for substrate specificity but not 
for substrate binding affinity [82], while loop 1 of A3H especially residue R26, plays a triple 
role for RNA binding, DNA substrate recognition, and catalytic activity likely by positioning the 
DNA substrate in the active site for effective catalysis [83]. In accordance with this, our study 
claims that 25RK26 substitution in loop 1 of A3C provides the microenvironment that drives the 
flexibility in substrate binding and enzymatic activity.  
The binding model developed here rationalizes how A3C variant C2 can interact with the 
negatively charged backbone of ssDNA via the positively charged loop 1 side chains of R25 and 
K26 (Fig. 8D). Like our modeling strategy, Fang et al. [78] used their binding mode model of 
A3F-CD2 with ssDNA to identify residues in the A3G-CTD important for ssDNA binding. 
Furthermore, the increased mobility of DNA binding regions carrying the substitutions in C2 
and hA3C-S61P.S188I, respectively, compared to hA3C (Suppl. Fig. S8) suggests that C2 and 
hA3C-S61P.S188I can better slide along the ssDNA than hA3C: The higher mobility of the 
residues may allow them to adapt more quickly to the passing ssDNA, which, paired with likely 
stronger interactions with the backbone of the ssDNA, may explain the increased deaminase 
activity. In addition, loop 7 exhibits a decreased mobility in both C2 and hA3C-S61P.S188I 
compared to hA3C, which was shown to be a predictor for higher deaminase activity, DNA 
binding, and substrate specificity of A3G and A3F, and reported to be also relevant for antiviral 
activity of A3B and A3D [73,84-86]. 
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Unexpectedly, our experiments also demonstrated that LINE-1 restriction by A3C which was 
reported earlier to be deaminase-independent [56], is enhanced after expression of the 
A3C.WE-RK variant. These data suggest that the reported RNA-dependent physical interaction 
between L1 ORF1p and A3C dimers might be mediated by A3C loop 1, is partly dependent on 
the two amino acids W25 and E26 and enhanced by the R25 and K26 substitutions. However, 
L1 inhibition by A3F was not significantly altered by the A3F.RK-WE mutations, clearly 
indicating that in A3F other regions (and NTD) are likely to be relevant for L1 restriction. 
Because selection likely had to balance between anti-viral/anti-L1 activity and genotoxicity of 
A3 proteins, we wanted to characterize loop 1 residues during the evolution of closely related 
A3Z2 proteins such as A3C, A3D CTD and A3F CTD in primates. In the most recent common 
ancestor of these enzymes, before the split Catarrhini-Platyrrhini some 43 Mya, the sequence 
of this motif in loop 1 is LRKAYG. In New World Monkeys, the A3C genes were not duplicated 
and are basal to the three sister clades of Catarrhini A3C, A3D-CTD, and A3F-CTD. In extant 
A3C sequences in New World monkeys, the loop 1 motif has notably remained unchanged and 
reads LRKAYG. In Catarrhini, on the contrary, the ancestral A3C sequence underwent two rapid 
rounds of duplication that occurred after the split with the ancestor of Platyrrhini, and before 
the split between the ancestors of Cercopithecoidea and Hominoidea, some 29 Mya. In extant 
A3F-CTD sequences, the consensus form of the loop 1 remains LRKAYG, albeit with certain 
variability of the Arg residue to be exchanged by other positively charged amino acids. In 
extant A3D-CTD enzymes, this motif has undergone erosion, is more variable and reads 
L[RLQ][KT]A[YC]G. Interestingly, loop 1 in A3C has experienced rapid and swift selective 
pressure to exchange the positively charged RK amino acids by the largely divergent chemistry 
of WE, yielding LWEAYG. This selective sweep occurred very rapidly, as this is the fixed form 
in all Catarrhini. Notoriously, and exclusively in the Chlorocebus lineage, this amino acid 
substitution was partly reverted to LREAYG, which is the conserved sequence in the four 
Chlorocebus A3C entries available.  
Overall, our results suggest that the two duplication events that generated the extant A3C, 
A3D-CTD, and A3F-CTD sequences in Catarrhines, released the selective pressure on two of 
the daughter enzymes allowing them to explore the sequence space and to evolve via 
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sub/neofunctionalisation, as proposed for Ohno’s in-paralogs [87]. Thus, the A3F-CTD form of 
the loop 1 diverged little from the ancestral chemistry and possibly maintained the ancestral 
function, while the release in conservation pressure on A3D-CTD allowed the enzyme loop 1 
to accumulate mutations and diverge from the ancestral state. In turn, A3C was rapidly 
engaged into a distinct evolutionary pathway, which is unique due to the highly divergent 
chemistry of loop 1 but also because A3C is the only A3Z2 monodomain enzyme of the A3 
family.  
In conclusion, we postulate that the loop 1 region of A3s might have a conserved role in 
anchoring ssDNA substrate for efficient catalysis and that hA3C’s weak deamination and anti-
HIV-1 activity might have been the result of losing DNA interactions in loop 1 during its 
evolution. It is thus possible that genes encoding A3C proteins with loop 1 residues with a 
higher ssDNA affinity were too genotoxic to benefit its host by superior anti-viral and anti-L1 
activity. 
 
MATERIALS AND METHODS 
Cell culture. HEK293T cells were maintained in Dulbecco’s high-glucose modified Eagle’s 
medium (DMEM) (Biochrom, Berlin, Germany), supplemented with 10% fetal bovine serum 
(FBS), 2 mM L-glutamine, 50 units/ml penicillin, and 50 µg/ml streptomycin at 37°C in a 
humidified atmosphere of 5% CO2. Similarly, HeLa-HA cells [88] were cultured in DMEM with 
10% FCS (Biowest, Nuaillé, France), 2mM L-glutamine and 20 U/ml penicillin/streptomycin 
(Gibco, Schwerte, Germany).  
 
Plasmids. The HIV-1 packaging plasmid pMDLg/pRRE encodes gag-pol, and the pRSV-Rev for 
the HIV-1 rev [89]. The HIV-1 vector pSIN.PPT.CMV.Luc.IRES.GFP expresses the firefly 
luciferase and GFP reported previously [90]. HIV-1 based viral vectors were pseudotyped using 
the pMD.G plasmid that encodes the glycoprotein of VSV (VSV-G). SIVagm luciferase vector 
system was described before [31]. All APOBEC3 constructs described here were cloned in 
pcDNA3.1 (+) with a C-terminal hemagglutinin (HA) tag. The smmA3C-like expression plasmid 
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was generated by exon assembly from the genomic DNA of white-crowned mangabey 
(Cercocebus torquatus lunulatus), and the cloning strategy for smmA3C-like and the chimeras 
of hA3C/smmA3C-like plasmid construction was recently described [64]. The expression 
vector for A3G-HA was generously provided by Nathaniel R. Landau. Expression constructs 
hA3C, rhA3C, cpzA3C, agmA3C and A3C point mutant A3C.C97S were described before 
[52,55,65]. smmA3C-like with C-terminal V5 tag was cloned using following primers forward 
5'-EcoRI-ATGAATTCGCCACCATGAATCCACAGATCAGAAAC and reverse 5’-NotI-
ATGCGGCCGCCACTCGAGAATCTCCTGTAGGCGTC. 
Various point mutants hA3C.WE-RK, hA3C.ND-YG, hA3C.WE-RK.C97S, hA3C.WE-RK.S61P, 
hA3C.WE-RK.S61P.C97S, hA3C.WE-RK.S61P.S188I, hA3C.WE-RK.S61P.S188I.C97S, hA3F.RK-
WE, smmA3C-like.E68A were generated by using site-directed mutagenesis. Similarly, single 
or multiple amino acid changes were made in expression vectors to produce chimera 2 
mutants (C2.DH-YG, C2.RKYG-WEND, C2.R25W, C2.K26E, C2.Y28N, and C2.G29D) and 
smmA3C-like.RKYG-WEND. To clone C-terminal GST-tagged hA3C, hA3C.WE-RK, the ORFs 
were inserted between the restriction sites HindIII and XbaI in the mammalian expression 
construct pK-GST mammalian expression vector [91]. Individual exons of authentic smmA3C 
and smmA3F and smmA3F-like genes exons were amplified and cloned in pcDNA3.1. All the 
primer sequences are listed in Suppl. table 1. 
 
Virus production and isolation. HEK293T cells were transiently transfected using 
Lipofectamine LTX and Plus reagent (Invitrogen, Karlsruhe, Germany) with an appropriate 
combination of HIV-1 viral vectors (600 ng pMDLg/pRRE, 600 ng pSIN.PPT.CMV.Luc.IRES.GFP, 
250 ng pRSV-Rev, 150 ng pMD.G with 600 ng A3 plasmid or replaced by pcDNA3.1, unless 
otherwise mentioned) or SIVagm vectors (1400 ng pSIVTan-LucΔvif, 150 ng pMD.G with 600 
ng A3 plasmid) in 6 well plate. 48 h post-transfection, virion containing supernatants were 
collected and for isolation of virions, concentrated by layering on 20% sucrose cushion and 
centrifuged for 4 h at 14,800 rpm. Viral particles were re-suspended in mild lysis buffer (50 
mM Tris (pH 8), 1 mM PMSF, 10% glycerol, 0.8% NP-40, 150 mM NaCl and 1X complete 
protease inhibitor).  
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 






Luciferase-based infectivity assay. HIV-1 luciferase reporter viruses were used to transduce 
HEK293T cells. Prior infection, the amount of reverse transcriptase (RT) in the viral particles 
was determined by RT assay using Cavidi HS kit Lenti RT (Cavidi Tech, Uppsala, Sweden). 
Normalized RT amount equivalent viral supernatants were transduced. 48 h later, luciferase 
activity was measured using SteadyliteHTS luciferase reagent substrate (Perkin Elmer, Rodgau, 
Germany) in black 96-well plates on a Berthold MicroLumat Plus luminometer (Berthold 
Detection Systems, Pforzheim, Germany). Transductions were done in triplicate and at least 
three independent experiments were performed. 
 
Immunoblot analyses. Transfected HEK293T cells were washed with phosphate-buffered 
saline (PBS) and lysed in radioimmunoprecipitation assay buffer (RIPA, 25 mM Tris (pH 8.0), 
137 mM NaCl, 1% glycerol, 0.1% SDS, 0.5% sodium deoxycholate, 1% Nonidet P-40, 2 mM 
EDTA, and protease  inhibitor cocktail set III [Calbiochem, Darmstadt, Germany].) 20 min on 
ice. Lysates were clarified by centrifugation (20 min, 14800 rpm, 4°C). Samples (cell/viral 
lysate) were boiled at 95⁰C for 5 min with Roti load reducing loading buffer (Carl Roth, 
Karlsruhe, Germany) and subjected to SDS-PAGE followed by transfer (Semi-Dry Transfer Cell, 
Biorad, Munich, Germany) to a PVDF membrane (Merck Millipore, Schwalbach, Germany). 
Membranes were blocked with skimmed milk solution and probed with appropriate primary 
antibody, mouse anti-hemagglutinin (anti-HA) antibody (1:7,500 dilution, MMS-101P, 
Covance, Münster, Germany); mouse α-V5 antibody (1: 4000 dilution; Serotec); goat anti-
GAPDH (C-terminus, 1:15,000 dilution, Everest Biotech, Oxfordshire, UK); mouse anti-α-
tubulin antibody (1:4,000 dilution, clone B5-1-2; Sigma-Aldrich, Taufkirchen, Germany), 
mouse anti-capsid p24/p27 MAb AG3.0 [92] (1:250 dilution, NIH AIDS Reagents); rabbit anti 
S6 ribosomal protein (5G10; 1:103 dilution in 5% BSA, Cell Signaling Technology, Leiden, The 
Netherlands). Secondary Abs.: anti-mouse (NA931V), anti-rabbit (NA934V) horseradish 
peroxidase (1:104 dilution, GE Healthcare) and anti-goat IgG-HRP (1:104 dilution, sc-2768, 
Santa Cruz Biotechnology, Heidelberg, Germany). Signals were visualized using ECL 
chemiluminescent reagent (GE Healthcare). To characterize the effect of the expression of A3 
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 





proteins and their mutants on LINE-1 (L1) reporter expression, HeLa-HA cells were lysed 48 h 
post-transfection using triple lysis buffer (20 mM Tris/HCl, pH 7.5; 150 mM NaCl; 10 mM EDTA; 
0.1% SDS; 1% Triton X-100; 1% deoxycholate; 1x complete protease inhibitor cocktail [Roche]), 
clarified and 20 μg total protein were used for SDS-PAGE followed by electroblotting. HA-
tagged A3 proteins and L1 ORF1p were detected using an anti-HA antibody (Cat.# MMS-101P; 
Covance Inc.) in a 1:5,000 dilution and the polyclonal rabbit-anti-L1 ORF1p antibody #984 [93]  
in a 1:2,000 dilution, respectively, in 1xPBS-T containing 5% milk powder. ß-actin expression 
(clone AC-74, 1:30,000 dilution, Sigma-Aldrich Chemie GmbH) served as a loading control.   
 
Differential DNA denaturation (3D) PCR. HEK293T cells were cultured in 6-well plates and 
infected with DNAse I (Thermo Fisher Scientific, Schwerte, Germany) treated viruses for 12 
hours. Cells were harvested and washed in PBS, the total DNA was isolated using DNeasy DNA 
isolation kit (Qiagen, Hilden, Germany). A 714-bp fragment of the luciferase gene was 
amplified using the primers 5’-GATATGTGGATTTCGAGTCGTC-3’ and 5’-
GTCATCGTCTTTCCGTGCTC-3’. For selective amplification of the hypermutated products, the 
PCR denaturation temperature was lowered stepwise from 87.6°C to 83.5°C (83.5°C, 84.2°C, 
85.2°C, 86.3°C, 87.6°C) using a gradient thermocycler. The PCR parameters were as follows: (i) 
95°C for 5 min; (ii) 40 cycles, with 1 cycle consisting of 83.5°C to 87.6°C for 30 s, 55°C for 30 s, 
72°C for 1 min; (iii) 10 min at 72°C. PCRs were performed with Dream Taq DNA polymerase 
(Thermo Fisher Scientific). PCR products were stained with ethidium bromide. PCR product 
(smmA3C-like sample only) from the lowest denaturation temperature was cloned using 
CloneJET PCR Cloning Kit (Thermo Fisher Scientific) and sequenced. smmA3C-like protein-
induced hypermutations of eleven independent clones were analysed with the Hypermut 
online tool (https://www.hiv.lanl.gov/content/sequence/HYPERMUT/hypermut.html) [94]. 
Mutated sequences (clones) carrying similar base changes were omitted and only the unique 
clones were presented for clarity. 
 
In vitro DNA cytidine deamination assay. A3 proteins expressed in transfected HEK293T cells 
or virion incorporated A3s used as input. Cell lysates were prepared with mild lysis buffer 48 
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h post plasmid transfection. Deamination reactions were performed as described [67,95] in a 
10 µL reaction volume containing 25 mM Tris pH 7.0, 2 µl of cell lysate and 100 fmol single-
stranded DNA substrate (TTCA: 5’-
GGATTGGTTGGTTATTTGTATAAGGAAGGTGGATTGAAGGTTCAAGAAGGTGATGGAAGTTATGTTT
GGTAGATTGATGG). Samples were treated with 50 µg/ml RNAse A (Thermo Fisher Scientific). 
Reactions were incubated for 1 h at 37˚C and the reaction was terminated by boiling at 95˚C 
for 5 min. One fmol of the reaction mixture was used for PCR amplification Dream Taq 
polymerase (Thermo Fisher Scientific) 95˚C for 3 min, followed by 30 cycles of 61˚C for 30 s 
and 94˚C for 30 s) using primers forward 5’-GGATTGGTTGGTTATTTGTATAAGGA and reverse 
5'-CCATCAATCTACCAAACATAACTTCCA. PCR products were digested with MseI (NEB, 
Frankfurt/Main, Germany), and resolved on 15% PAGE, stained with ethidium bromide (7.5 
μg/ml). As a positive control, substrate oligonucleotides with TTUA instead of TTCA were used 
to control the restriction enzyme digestion [65].  
 
L1 retrotransposition assay. Relative L1 retrotransposition activity was determined by 
applying a rapid dual-luciferase reporter based assay described previously [76]. Briefly, 2x105 
HeLa-HA cells were seeded per well of a six-well plate and transfected using Fugene-HD 
transfection reagent (Promega) according to the manufacturer’s protocol. Each well was 
cotransfected with 0.5 g of the L1 retrotransposition reporter plasmid pYX017 or pYX015 [76] 
and 0.5 g of pcDNA3.1 or wild-type or mutant A3 expression construct resuspended in 3 l 
Fugene-HD transfection reagent and 100 l GlutaMAX-I-supplemented Opti-MEM I reduced-
serum medium (Thermo Fisher Scientific). Three days after transfection cultivation, the 
medium was replaced by complete DMEM containing 2.5 g/ml puromycin, to select for the 
presence of the L1 reporter plasmid harboring a puroR-expression cassette. Next day, the 
medium was replaced once more by puromycin containing DMEM medium and 48 hours later, 
transfected cells were lysed to quantify dual-luciferase luminescence. Dual-luciferase 
luminescence measurement: Luminescence was measured using the Dual-Luciferase Reporter 
Assay System (Promega) following the manufacturer’s instructions. For assays in 6-well plates, 
200 l Passive Lysis Buffer was used to lyse cells in each well; for all assays, 20 l lysate was 
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transferred to a solid white 96-well plate, mixed with 50 l Luciferase Assay Reagent II and 
firefly luciferase (Fluc) activity was quantified using the microplate luminometer Infinite 
200PRO (Tecan, Männedorf, Switzerland). Renilla luciferase (Rluc) activity was subsequently 
read after mixing 50 l Stop & Glo Reagent into the cell lysate containing Luciferase Assay 
Reagent II. Data were normalized as described in the results section. We routinely used the 
retrotransposition-defective L1RP/JM111 (located on pYX015) as the reference Fluc vector 
and set normalized luminescence ratio (NLR) resulting from cotransfection of pYX015 and 
pcDNA3.1(+) as 1. 
 
Protein sequence alignment and visualization. Sequence alignment of hA3C and smmA3C-
like protein was done by using Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/). 
The alignment file was then submitted to ESPript 3.0 [96] (espript.ibcp.fr) to calculate the 
similarity and identity of residues between both proteins and to build the alignment figure. 
Cartoon model of the crystal structure of A3C (PDB 3VOW) was constructed using PyMOL 
(PyMOL Molecular Graphics System version 1.5.0.4; Schrödinger, Portland, OR). 
  
Protein structural model building. The structural models of hA3C or C2 binding to ssDNA were 
generated by first aligning the X-ray crystal structure of rhA3G-NTD (PDB ID 5K82 [77]) onto 
the X-ray crystal structure of hA3F-CTD (PDB ID 5W2M [78]), the latter of which was co-
crystallized with ssDNA. Subsequently, the hA3C X-ray crystal structure (PDB ID 3VOW [63]) 
was aligned onto the NTD of rhA3G, which is structurally similar to hA3C. The ssDNA and the 
interface region of hA3C were subsequently relaxed in the presence of each other using 
Maestro [97]. The same program was used to mutate hA3C to obtain the C2 and 
hA3C.S61P.S188I variants, which was again relaxed in the presence of the ssDNA. Similarly, we 
obtained a C2 ssDNA binding model based on the ssDNA-binding X-ray crystal structure of 
hA3A (PDB ID 5SWW [98]).  
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The alignment of the sequences of the crystal structures was generated with Probcons [99], 
accessed through Jalview [100], which was also used to visualize the alignment (Suppl. Fig. 
S9). 
hA3C, C2, and hA3C.S61P.S188I were subjected to MD simulations. For this, the above-
mentioned structures without the DNA were N- and C-terminally capped with ACE and NME, 
respectively. The three variants were protonated with PROPKA [101] according to pH 7.4, 
neutralized by adding counter ions, and solvated in an octahedral box of TIP3P water [102] 
with a minimal water shell of 12 Å around the solute. The Amber package of molecular 
simulation software [103] and the ff14SB force field [104] was used to perform the MD 
simulations. For the Zn2+-ions the Li-Merz parameters for two-fold positively charged metal 
ions [105] were used. To cope with long-range interactions, the “Particle Mesh Ewald” method 
[106] was used; the SHAKE algorithm [107] was applied to bonds involving hydrogen atoms. 
As hydrogen mass repartitioning [108] was utilized, the time step for all MD simulations was 
4 fs with a direct-space, non-bonded cut-off of 8 Å. In the beginning, 17500 steps of steepest 
descent and conjugate gradient minimization were performed; during 2500, 10000, and 5000 
steps positional harmonic restraints with force constants of 25 kcal mol-1 Å-2, 5 kcal mol-1 Å-2, 
and zero, respectively, were applied to the solute atoms. Thereafter, 50 ps of NVT (constant 
number of particles, volume, and temperature) MD simulations were conducted to heat up 
the system to 100 K, followed by 300 ps of NPT (constant number of particles, pressure, and 
temperature) MD simulations to adjust the density of the simulation box to a pressure of 1 
atm and to heat the system to 300 K. During these steps, a harmonic potential with a force 
constant of 10 kcal mol-1 Å-2 was applied to the solute atoms. As the final step in 
thermalization, 300 ps of NVT-MD simulations were performed while gradually reducing the 
restraint forces on the solute atoms to zero within the first 100 ps of this step. Afterwards, 
five independent production runs of NVT-MD simulations with 2 s length each were 
performed. For this, the starting temperatures of the MD simulations at the beginning of the 
thermalization were varied by a fraction of a Kelvin. 
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Expression and purification of recombinant GST-tagged hA3C and hA3C.WE-RK from 
HEK293T cells. Recombinant C-terminal GST-tagged hA3C and hA3C.WE-RK were expressed in 
HEK293T cells and purified by affinity chromatography using Glutathione Sepharose 4B beads 
(GE Healthcare) as described previously [65]. Cells were lysed 48 h later with mild lysis buffer 
[50 mM Tris (pH 8), 1 mM PMSF, 10% glycerol, 0.8% NP-40, 150 mM NaCl, and 1X complete 
protease inhibitor and incubated with GST beads. After 2 h incubation at 4°C in end-over-end 
rotation, GST beads were washed twice with wash buffer containing 50 mM Tris (pH 8.0), 5 
mM 2-ME, 10% glycerol and 500 mM NaCl. The bound GST hA3C and hA3C.WE-RK proteins 
were eluted with wash buffer containing 20 mM reduced glutathione. The proteins were 90-
95% pure as checked on 15% SDS-PAGE followed by Coomassie blue staining. Protein 
concentrations were estimated by Bradford's method. 
 
Electrophoretic mobility shift assay (EMSA) with hA3C-GST and hA3C.WE-RK-GST. EMSA was 
performed as described previously [65,79,109]. We mixed 20 fmol of 3′ biotinylated DNA (30-
TTC-Bio-TEG purchased from Eurofins Genomics, Ebersberg Germany) with 10 mM Tris (pH − 
7.5), 100 mM KCl, 10 mM MgCl2, 1 mM DTT, 2% glycerol, and the respective amount of 
recombinant proteins in a 15 μl reaction mixture, and incubated at room temperature for 30 
min. The reaction mixture containing the protein–DNA complex were resolved on a 5% native 
PAGE gel on ice and transferred to a nylon membrane (Amersham Hybond-XL, GE healthcare) 
using 0.5 X TBE. After the transfer, the membrane containing protein–DNA complex were 
cross-linked by UV radiation with 312-nm bulb for 15 min. Chemiluminescent detection of 
biotinylated DNA was carried out according to the manufacturer's instruction (Thermo 
Scientific LightShift Chemiluminescence EMSA Kit). 
 
Phylogenetic inference. In order to study the evolution of the A3-Z2 domains a representative 
set of 62 primate A3C, A3D, and A3F gene sequences were collected from GenBank 
(https://www.ncbi.nlm.nih.gov/genbank), as follows: 26 A3C sequences, 12 A3D sequences, 
and 21 A3F sequences. The phylogenetic relationships and divergence times among the 
species used were retrieved from http://www.timetree.org (Suppl. Fig. S10). A3 sequences 
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from the northern tree shrew Tupaia belangeri were included as an outgroup to the primate 
ones. As A3D and A3F sequences contain each two Z2 domains, they were split into the 
corresponding N- and C-termini. The alignments were performed at the amino acid level using 
MAFFTv7.380 (http://mafft.cbrc.jp/alignment/software/) [110]. Phylogenetic inference was 
performed using RAxMLv8 [111], at either the nucleotide level under the GTR+ model or at 
the amino acid level under the LG+ model. Node support was evaluated applying 5,000 
bootstrap cycles. Phylogenies at the nucleotide level were also calculated after introducing 
constraints in the tree, forcing monophyly of each clade A3D_N and C-termini, A3F_N and C-
termini, New World monkeys A3C, and catarrhine A3C. Differences in maximum likelihood 
between alternative topologies for the same alignment were evaluated by the Shimodaira-
Hasegawa test. Ancestral state reconstruction of amino acids in the loop A3_Z2 loop1 was 
performed only for the supported clades using RAxMLv8. A tanglegram with the two 
phylogenies was drawn with Dendroscope v3.6.3 [112]. Final layouts were done with Inkscape 
0.92.4. 
 
Statistical analysis. Data were represented as the mean with SD in all bar diagrams. 
Statistically significant differences between two groups were analyzed using the unpaired 
Student’s t-test with GraphPad Prism version 5 (GraphPad Software, San Diego, CA, USA). A 
minimum p-value of 0.05 was considered as statistically significant. 
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Figure 1. A3C-like protein from sooty mangabey but not A3C from any orthologue inhibits 
HIV1Δvif by more than an order of magnitude. (A) HIV-1Δvif particles were produced with 
A3C from human, rhesus macaque, chimpanzees (cpz), African green monkey (agm), and A3C-
like protein from sooty mangabey monkey (smm), hA3G or vector only. Infectivity of (RT-
activity normalized) equal amounts of viruses, relative to the virus lacking any A3, was 
determined by quantification of luciferase activity in HEK293T cells. Presented values are 
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means ± standard deviations (error bars) for three independent experiments. Unpaired t-tests 
were computed to determine whether differences between vector and each A3 protein reach 
the level of statistical significance. Asterisks indicate statistically significant differences: ***, p 
< 0.0001. (B) Immunoblot analysis of HA-tagged A3 and HIV-1 capsid expression in cell lysates 
using anti-HA and anti p24 antibodies, respectively. GAPDH served as a loading control. “α” 
represents anti. Viral encapsidation of hA3G, hA3C, and smmA3C-like protein is demonstrated 
in Suppl. Fig. S1. (C) 3D-PCR: HIV-1Δvif produced together with A3C orthologues, hA3G or 
vector controls were used to transduce HEK293T cells. Total DNA was extracted and a 714-bp 
fragment of reporter viral DNA was selectively amplified using 3D-PCR. Td = denaturation 
temperature. Extensive viral DNA editing profile of smmA3C-like protein and its relative 
positions of GA transition mutations are presented in Suppl. Fig. S5. (D) In vitro deamination 
activity of A3Cs encapsidated in HIV-1Δvif, and SIVagmΔvif particles. Virions were 
concentrated and lysed in mild lysis buffer and an equal amount of lysate were used for the 
assay. Numbers 1 and 10 indicate 60 ng and 600 ng of A3 expression vector used for 
transfection, respectively. Samples were treated with RNAse A; oligonucleotide-containing 
uracil (U) instead of cytosine served as a marker to denote the migration of deaminated 









.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 







Figure 2. Anti-HIV-1 activity of hA3C/smmA3C-like protein chimeras. (A) Structures of the 
generated chimeras between A3C and smmA3C-like protein. Grey and white boxes indicate 
fractions of A3C and the smmA3C-like protein, respectively. Each chimera (C) encompasses 
190 amino acids. Amino acid position (number) at the breakpoints of each chimera is 
indicated. Please find protein sequence and alignment presented in Suppl. Fig. S4A. (B) HIV-
1Δvif particles were produced with A3C from human, smm (A3C-like), and h/smm chimeras or 
vector only. Infectivity of (RT-activity normalized) equal amounts of viruses, relative to the 
virus lacking any A3, was determined by quantification of luciferase activity in HEK293T cells. 
Values are means ± standard deviations (error bars) for three independent experiments. 
Unpaired t-tests were computed to determine whether differences between vector and each 
A3 protein reach the level of statistical significance. Asterisks represent statistically significant 
differences: ***, p < 0.0001. (C) A3 expression in the cell lysates of transfected cells and A3 
viral incorporation were determined by immunoblotting. A3s and HIV-1 capsids were stained 
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with anti-HA and anti-p24 antibodies, respectively. GAPDH served as a loading control. “α” 
represents anti. (D) To examine the catalytic activity of A3C chimeras, in vitro deamination 
assays were performed using lysates of cells that were previously transfected with respective 
expression plasmids. RNAse-treatment was included in samples (ten h/smm A3C chimeras, 
hA3C and smmA3C-like protein) subjected to this assay; oligonucleotide containing uracil (U) 
instead of cytosine served as a marker to denote the migration of deaminated product after 
restriction enzyme cleavage. S-substrate, P-product. 
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Figure 3. Identification of the A3Z2 domain mediating enhanced antiviral activity. (A) 
Illustration of chimera 2 (C2) and variants of C2 or smmA3C-like protein having amino acid 
exchanges in the DHIH (circle) or RKYG (square) motif. The red triangle denotes catalytic 
residue E68A mutation. Amino acid position (number) at the breakpoints of each chimera is 
indicated. Please see Suppl. Fig. S4 for more details about the sequence and structure of these 
motifs. (B) To examine the catalytic activity of chimeras C2 and its variants, in vitro 
deamination assays were performed using lysates of transfected cells. RNAse A-treatment was 
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included; oligonucleotide containing uracil (U) instead of cytosine served as a marker to 
denote the migration of deaminated product after restriction enzyme cleavage. S-substrate, 
P-product. Immunoblot shows the amount of proteins produced in the transfected cells (lower 
panel). A3s were stained with anti-HA antibody and tubulin served as a loading control. “α” 
represents anti. (C) HIV-1Δvif particles were produced with C2 and its variants or vector only. 
Infectivity of (RT-activity normalized) equal amounts of viruses, relative to the virus lacking 
any A3, was determined by quantification of luciferase activity in HEK293T cells. Values are 
means ± standard deviations (error bars) for three independent experiments. Unpaired t-tests 
were computed to determine whether differences between vector and each A3 protein reach 
the level of statistical significance. Asterisks represent statistically significant differences: ***, 
p < 0.0001; ns, not significant. (D) Amount of proteins in the cell lysate and viral encapsidation 
of C2 or its variants were determined by immunoblotting. C2/variants and HIV-1 capsids were 
stained with anti-HA and anti-p24 antibodies, respectively. Tubulin served as a loading control. 
(E) Quantification of hypermutations in viral DNA by 3D-PCR. HIV-1Δvif particles produced in 
the presence of overexpressed C2, C2.DH-YG, C2.RKYG-WEND or vector controls were used to 
transduce HEK293T cells. Total DNA was extracted and a 714-bp fragment of reporter viral 
DNA was selectively amplified using 3D-PCR. Td = denaturation temperature. 
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Figure 4. RKYG-WEND exchange in smmA3C-like protein abrogates its antiviral activity. (A) 
HIV-1Δvif particles were produced with smmA3C-like protein, its mutants E68A (catalytically 
inactive), RKYG-WEND or vector only. Infectivity of (RT-activity normalized) equal amounts of 
viruses, relative to the virus lacking any A3, was determined by quantification of luciferase 
activity in HEK293T cells. (B) Immunoblot analyses were performed to quantify HA-tagged A3 
proteins and viral p24 proteins in cellular and viral lysates using anti-HA and anti-p24 
antibodies, respectively. Tubulin served as a loading control. “α” represents anti. (C) 
Quantification of hypermutation in viral DNA by 3D-PCR. HIV-1Δvif particles produced in the 
presence of overexpressed smmA3C-like protein, its variants or vector control were used to 
transduce HEK293T cells. Total DNA was extracted and a 714-bp fragment of reporter viral 
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Figure 5. A3C gains deaminase-dependent anti-HIV-1 activity by a WE-RK change in loop 1. 
(A) HIV-1Δvif particles were produced with hA3C, its mutants (C97S, S61P, S188I, WE-RK, ND-
YG) or vector only. Infectivity of equal amounts of viruses (RT-activity normalized), relative to 
the virus lacking any A3C, was determined by quantification of luciferase activity in HEK293T 
cells. (B) HIV-1Δvif particles were produced with hA3C, its variants such as, C97S, WE-RK, WE-
RK.C97S, WE-RK.S61P, WE-RK.S61P.C97S, WE-RK.S61P.S188I, WE-RK.S61P.S188I.C97S or 
vector only. Infectivity of equal amounts of viruses (RT-activity normalized), relative to the 
virus lacking any A3C, was determined by quantification of luciferase activity in HEK293T cells. 
(C) Quantification of HA-tagged wild-type and mutant A3C proteins in both cellular and viral 
lysates by immunoblot analysis. A3s and HIV-1 capsids were stained with anti-HA and anti-p24 
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antibodies, respectively. Tubulin served as a loading control. “α” represents anti. (D) 3D-PCR: 
HIV-1Δvif produced together with hA3C, its variants (as in Fig. 5B), or vector controls were 
used to transduce HEK293T cells. Total DNA was extracted and a 714-bp fragment of reporter 
viral DNA was selectively amplified using 3D-PCR. Td = denaturation. Please see Suppl. Fig. S6 
for the 3D-PCR data of mutants S61P and S188I. (E) In vitro deamination assays to examine 
the catalytic activity of A3C and its variants using lysates of cells that were previously 
transfected with respective expression plasmids (as in Fig. 5B). RNAse A-treatment was 
included; oligonucleotide containing uracil (U) instead of cytosine served as a marker to 
denote the migration of deaminated product after restriction enzyme cleavage. S-substrate, 
P-product. The two lower panels represent immunoblot analyses of expression levels of HA-
tagged A3C and mutant proteins ( HA (A3C)) and tubulin ( tubulin) which was used as a 
loading control. 
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Figure 6. Mutations in loop 1 of A3F-CTD moderately affect the antiviral activity of A3F. (A) 
Immunoblot analyses were performed to quantify the amounts of HA-tagged wild-type hA3C 
and hA3F proteins and their loop 1 mutants in cell lysates and viral particles.  HA-tagged A3s 
and HIV-1 capsid proteins were stained with anti-HA and anti-p24 antibodies, respectively. 
Tubulin served as a loading control. “α” represents anti. (B) Infectivity of equal amounts of 
HIV-1Δvif viruses (RT-activity normalized) encapsidating hA3C, hA3F, or their loop 1 mutants 
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relative to the virus lacking any A3 protein was determined by quantification of luciferase 
activity in transduced HEK293T cells. (C) 3D-PCR: HIV-1Δvif produced together with hA3C, 
hA3F, and their loop 1 mutants or vector control were used to transduce HEK293T cells. Total 
DNA was extracted and a 714-bp fragment of reporter viral DNA was selectively amplified 
using 3D-PCR. Td = denaturation temperature. (D) In vitro deamination assay to examine the 
catalytic activity of hA3C, hA3F, and their loop variants was performed using lysates of cells 
that were transfected with the respective A3 expression plasmids. RNAse A-treatment was 
included; oligonucleotide containing uracil (U) instead of cytosine served as a marker to 
denote the migration of the deaminated products after restriction enzyme cleavage. S-
substrate, P-product. The two lower panels represent immunoblot analyses of expression 
levels of HA-tagged A3C, A3F and mutant proteins ( HA (A3s)) and tubulin ( tubulin) which 
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Figure 7. Expression of the hA3C.WE-RK variant enhances A3C-mediated L1 restriction 
significantly. Dual-luciferase reporter assay to evaluate the effect of wild-type and mutant A3 
proteins on L1 retrotransposition activity. (A) Schematic of the L1 retrotransposition reporter 
construct pYX017 [76]. The L1Rp reporter element is under transcriptional control of the CAG 
promoter and a polyadenylation signal (A1) at its 3‘end. The firefly luciferase (Fluc) cassette 
has its own promoter (P2) and polyadenylation signal (A2), is expressed from the antisense 
strand relative to the CAG promoter, and interrupted by an intron (with splice donor SD and 
splice acceptor SA) in the transcriptional orientation of the L1 reporter element. (B) Effect of 
wild-type and mutant A3 proteins on L1 retrotransposition activity indicated by normalized 
luminescence ratio (NLR). NLR indicating retrotransposition activity observed after 
cotransfection of pYX015 and empty pcDNA3.1 (+) expression plasmid was set as 1. Error bars 
indicate standard deviation (N=4). The protein expression level of A3s is presented in Suppl. 
Fig. S7.  
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 







Figure 8. Model of A3C.WE-RK and ssDNA interaction. (A) Binding mode model of ssDNA 
(orange) to hA3C variant C2 based on hA3A. The side chains of the residues that are different 
between the hA3C WT and the C2 variant are shown in dark blue and labelled. The cytidine in 
the active center of C2 is shown in green. (B) Binding mode model of ssDNA (orange) to hA3C 
WT based on hA3F-CTD and rhA3G-NTD. Magnifications of the active center (green box) are 
shown at the bottom for hA3C WT (C) and C2 (D). The side chains of residues in the active 
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center that differ between hA3C WT and the C2 variant are shown in cyan and dark blue, 
respectively. The Zn2+ ion in the active center is shown as a sphere. Ongoing from hA3C WT to 
the C2 variant, the interface changes from being negatively to being positively charged. The 
flexible arginine and lysine side chains in the C2 variant can interact with the negatively 
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Figure 9. hA3C.WE-RK strongly interacts with ssDNA. (A) The purity of the recombinantly 
produced and affinity-purified proteins GST, A3C-GST, and A3C.WE-RK-GST was demonstrated 
by SDS-PAGE and subsequent Coomassie blue staining of the gel. The prestained protein 
ladder (M) indicates molecular mass. (B) EMSA with GST-tagged hA3C.WE-RK-GST and A3C-
GST produced in HEK293T cells was performed with 30-nt ssDNA target DNA labelled with 3′-
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labelled biotin. Indicated amounts of protein (at the bottom of the blot, in nm) were titrated 
with 20 fmol of DNA. Presence of competitor DNA (unlabeled 80-nt DNA used in deamination 
assay, 500-fold molar excess added) used to demonstrate the specific binding of the protein 




Figure 10A. Evolution of A3C/Z2. Tanglegram showing the maximum-likelihood amino acid-
based reconstructions of the A3 Z2 sequences in primates. The A3D and A3F proteins, 
containing each two Z2 domains, were split into N- and C-termini. The analyses were 
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performed at the Z2-domain level, labelled as follows: A3D-NTD, red; A3F-NTD, green; A3D-
CTD, light blue; A3F-CTD, dark blue; A3C, orange. The A3Z2 sequences of the northern tree 
shrew Tupaia belangeri were used as an outgroup. On the right, the phylogenetic 
reconstruction was built without any topological restriction. On the left, monophyly of the 
different Z2 domains was enforced, as indicated with the keyhole symbols of the 
corresponding color. Sequences with a significantly different position in the two trees are 
connected by a line. All A3C sequences are consistently monophyletic, and their phylogenetic 
relationships in the gene tree adhere to those of the species tree. Conversely, for Old World 
monkeys, sequences identified as A3D-CTD are in certain cases closest relatives of A3F-CTD, 
and vice versa. Such anomalies could have a methodological basis, such as poor annotation or 
overlooked chimeric amplification of closely related sequences into a single amplicon. 
Alternatively, they could be related to a genuine biological phenomenon of interlocus gene 
conversion, in which one allele (or one genomic stretch) is replaced by a paralogous allele with 
which it shares a high sequence identity. In this case, the NTD and the CTD of A3D and A3F 
share respectively very recent common ancestors. 
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Figure 10B. Evolution of A3C/Z2. Phylogenetic relationships between A3 Z2 sequences in 
primates, using A3 Z2 sequences in the northern tree shrew Tupaia belangeri genome as an 
outgroup (see Suppl. Fig. S10 for evolutionary relationships of analyzed species). The A3D and 
A3F proteins, containing each two Z2 domains, were split into NTD and CTD. The A3C 
sequences in the New World Monkeys (A3C_NWM) are monophyletic and constitute the sister 
taxa for A3C, A3D-CTD, and A3F-CTD. For each A3 Z2 sequence cluster, a sequence logo 
focused on loop 1 of the extant sequences is shown on the right. For the ancestor nodes that 
can be inferred with confidence, the most likely amino acid sequence of the ancestral state is 
provided. The last common ancestor of A3C, A3D-CTD and A3F-CTD likely presented a RKAYG 
sequence in the protein loop 1, and this sequence has been maintained in New World 
Monkeys’ A3Cs. However, this sequence stretch underwent a strong selective pressure and 
became the strongly divergent WEA[ND] [ND] in present-day A3Cs. Subsequently, and 
exclusively in A3C in the Chlorocebus genus, a secondary W>R reversion occurred. The 
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ancestral sequence was essentially maintained [RQ]KAYG in A3F-CTD, while it was largely 
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S1 Fig. Viral incorporation of A3s. Immunoblot analysis of HA-
tagged hA3G, hA3C, and smmA3C-like protein in lysates of
transfected cells (Cell) and HIV-1Δvif viral particles (Virus). A3s
were detected using anti-HA and anti p24 antibodies,




smmA3F-CTD 5 6 7
smmA3C 2 3 41
S2 Fig. The ORF of smmA3C-like is a hybrid sequence made by exonic sequences of smmA3C and smmA3F.
Arrangement of exons of the ORFs that produce smmA3C-like protein, smmA3C, and smmA3F-CTD. Purple and red
colors indicate exons derived from smmA3C and smmA3F, respectively. Note that smmA3F-CTD is encoded by exons 5,








S3 Fig. Expression and deamination activity of smmA3C and smmA3F-CTD (A) HEK293T cells were transfected
with expression plasmids encoding smmA3C, smmA3F-CTD, smmA3C-like protein and their mutants. Immunoblot
stained with anti-HA antibody, shows the amount of A3s in cell lysates. Tubulin served as a loading control. “α”
represent anti. (B) To examine the catalytic activity of smmA3C, smmA3C-like protein, and their variants, in vitro
deamination assay was performed using lysates of cells that were previously transfected with respective
expression plasmids. RNAse A-treatment was included; oligonucleotide containing uracil (U) instead of cytosine





S4 Fig. Protein sequence and structure information
of hA3C and smmA3C-like protein. (A) Sequence
alignment of hA3C and smmA3C-like protein was
done by using Clustal Omega and ESPript 3.0. Motif
1 (YGTQ) and motif 2 (WEND) are marked with red
boxes, red lollipops indicate active site amino acids
H66, E68, C97 and C100, while S61 and S188 are
colored in purple. (B) Ribbon model of the crystal
structure of A3C (PDB 3VOW) depicting the spatial
arrangements of helix 1 (YGTQ motif) and loop 1
(WEND motif). Residues of both motifs are
presented in purple. Key residues S61, S188, and
zinc-coordinating active site residues are denoted
as ball and sticks. Sphere represents Zn2+ ion.
3D-PCR sequences: HIV-1Δvif with smmA3C-like
GA: 17.16%n=327
S5 Fig.
S5 Fig. smmA3C-like protein mediated hypermutation of
HIV-1Δvif DNA. To characterize and quantify mutations
induced by smmA3C-like protein, the PCR product obtained
at the lowest denaturing temperature (shown in Fig. 1C and
marked with a red asterisk (*)) was cloned and a number of
independent clones were sequenced and analyzed. The
mutation pattern is presented using hypermut tool (note:
identical clones were omitted). Each of the sequences is
given as a horizontal line. Mutations were denoted as small
vertical lines. Red, cyan, magenta, green and black colored
lines represent GG-to-AG, GA-to-AA, GT-to-AT, GC-to-AC,
and non-G-to-A mutations, respectively. The overall
mutation load (GA) was given in the top ride side as %. ‘n’
denotes the total number of independent GA mutations
found in independent sequences.
S6 Fig.
S6 Fig. 3D-PCR analysis of hA3C mutants. HIV-1Δvif
produced together with hA3C, its variants (C97S, S61P,
S188I, WE-RK, WE-RK.S61P, ND-YG), or vector controls were
used to transduce HEK293T cells. Total DNA was extracted
and a 714-bp fragment of reporter viral DNA was selectively









































































S7 Fig. Expression of transfected A3- and L1-plasmids in
HeLa cells. Immunoblot analysis of the expression of A3C
and its mutants WE-RK, WE-RK.S61P, A3A, A3F, and its
mutant RK-WE after co-transfection with the L1 reporter
pYX017 into HeLa-HA cells. Expression of the L1 reporter and
A3 proteins was analyzed using antibodies against L1 ORF1p
(-ORF1p) or -HA, respectively. -actin protein levels were
analyzed as loading controls. Cell extracts from mock-
transfected HeLa-HA cells served as negative controls for L1-
ORF1p expression and HA-tagged A3 expression.
S8 Fig.
S8 Fig. Root mean square fluctuations of the residues in the hA3C, C2, and hA3C.S61P.S188I
variants over the course of 2 µs MD simulations. The RMSF are given as means over five
independent replicas for each variant ± SEM for all residues present in the X-ray structure of
A3C (PDB ID 3VOW). The residues lining the active center are marked by green boxes.
S9 Fig.
S9 Fig. Multiple sequence alignment of human A3C (ABC3C_HUMAN), rhesus macaque A3G
(M1GSK9_MACMU), human A3F (ABC3F_HUMAN), and chimpanzee A3H (B7T0U6_PANTR), in order.
The coloring of the residues depends on the physicochemical properties of conserved residues.
S10 Fig.
S10 Fig. Phylogenetic relationships and divergence times among the species used to
collect the A3Z2 sequences, were retrieved from http://www.timetree.org.
S1 table: List of oligonucleotides used in the study. 
 













hA3C.S61P-Fw AACCAGGTGGATCCTGAGACCCATTG hA3C point mutation 
hA3C.S61P-Re CAATGGGTCTCAGGATCCACCTGGTT hA3C point mutation 
hA3C.S188I-Fw GCTACGGGAGATTCTCCAG hA3C point mutation 









GST-hA3C, hA3C.WE-RK  cloning 
pK-GST-A3C-Re ATTCTAGACTGGAGACTCTCCCGTAGCC
T 
GST-hA3C, hA3C.WE-RK  cloning 
SmmA3C-like.E68A-
Fw 
CCATTGTCATGCAGCAAGGTGCTTCCTC smmA3C-like point mutation 
SmmA3C-like.E68A-Re   
GAGGAAGCACCTTGCTGCATGACAATG
G 
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C2 point mutation 
C2.R25W-Re CCGACCATAGGCTTTCCATAGGTTTTTA
AAGTG 
C2 point mutation 
C2.K26E-Fw TTTAAAAACCTACGGGAAGCCTATGGTC
GGAACG 
C2 point mutation 
C2.K26E-Re CGTTCCGACCATAGGCTTCCCGTAGGTT
TTTAAA 
C2 point mutation 
C2.Y28N-Fw AACCTACGGAAAGCCAATGGTCGGAAC
GAAAC 
C2 point mutation 
C2.Y28N-Re GTTTCGTTCCGACCATTGGCTTTCCGTA
GGTT 
C2 point mutation 
C2.G29D-Fw CCTACGGAAAGCCTATGATCGGAACGA
AACTTGGC 
C2 point mutation 
C2.G29D-Re GCCAAGTTTCGTTCCGATCATAGGCTTT
CCGTAGG 





Sooty A3C cloning 
SootyA3C.Exon1+2-Re CAATGGGTCTCAAGATCGACCTGGTTTT
GGAAGACGCCCC 
Sooty A3C cloning 
SootyA3C.Exon3-Fw GGGGCGTCTTCCAAAACCAGGTCGATC
TTGAGACCCATTG 
Sooty A3C cloning 
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SootyA3C.Exon3-Re TTCCCGACAATATTTAAAATCTTCGTAG
TCCATAATCTCC 
Sooty A3C cloning 
SootyA3C.Exon4-Fw GGAGATTATGGACTACGAAGATTTTAA
ATATTGTCGGGAA 
Sooty A3C cloning 
SootyA3C.Exon4-Re ATCGAATTCAGCGTAATCTGGAACATCG
TATGGGTACTCGAGAATCTCCTGTAG 
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